High-quality Immune Assessments
Given the growing number of biologics and immune-targeting drugs, the need to measure and predict the risk of adverse drug reactions in patients is urgent. Animal models fail to address questions related to both safety and effect – resulting in project delays, increased costs, and, above all, a non-optimized clinical program with inherent risks for trial participants.
We combine our strong scientific knowledge with a versatile preclinical platform – thereby addressing important questions related to the safety and function of biopharmaceuticals.
Our Services
Cytokine Release Assay
Evaluate the potential for cytokine release in a physiologically relevant environment.
Complement activation and inhibition
Simultaneous study of all complement responses - in one assay.
ADCC / CDC
Simultaneous study of ADCC and CDC offers several advantages - and is unique in preclinical testing.
Cell binding & activation
Analysis of all cells in the human circulation - in one assay.
Platelet Activation & Aggregation
Tailored platelet analysis including activation, aggregation, apoptosis, hemolysis & hemagglutination
Customize your project
Every drug development project comes with its own needs and challenges. At Immuneed, we provide our customers with a tailored solution in the early stages of development, enabling safe and effective drugs. All projects are fully customized and delivered in a flexible scientific report.
We’re happy to answer questions and get you acquainted with Immuneed – contact us today.
Customer promise
QUALITY:
Quality is reflected in everything we do. With ID.Flow's high predictive value, the platform brings you results that are relevant, reliable and reproducible.
TIME:
We compete not only on the quality and accuracy of data, but also on the speed of achieving it – which is why innovative biotech and agile pharma companies rely on us to ease their transition into the clinic.
FLEXIBILITY:
We tailor the study design based on your specific needs. You choose the number of read-outs, test substances and the level of reporting: “Brief, Standard or Tailored”.
IMMUNEED